New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform

World News: . []

HALIFAX Nova Scotia April 16 2018 GLOBE NEWSWIRE) -- Immunovaccine Inc TSXIMV OTCQXIMMVF a clinical stage immuno-oncology company, today announced that it presented new research on its T-cell activating platform at the In collaboratio n with ...

More news and information about Immunovaccine Inc.

Published By:

Globe Newswire: 14:05 GMT Monday 16th April 2018

Published: .

Search for other references to "preclinical" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us